BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20280326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20281029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250301T080000
DTEND;TZID=Europe/Vienna:20270330T170000
DTSTAMP:20260421T101950
CREATED:20251117T100100Z
LAST-MODIFIED:20251117T102105Z
UID:3297-1740816000-1806426000@esmit.eanm.org
SUMMARY:Fundamentals of Research in Imaging and Theranostics Part 2
DESCRIPTION:UEMS EACCME has granted the accreditation of 4.5 CME credits for this event. \n\n\n\n \n\n\n\n \n\n\n\nThis online course is part of a longer line of research methodology which is aimed at providing interested participants with information about the preclinical development and clinical translation\, as well as the design\, conductance and reporting of clinical research trials\, with a specific emphasis on radiopharmaceuticals for both diagnostic and therapeutic applications. \n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\nFor phase I/II clinical studies with radiopharmaceuticals to understand:    \n\n\n\n\nThe principles of technical realisation of the study including assessment of safety of investigational medicinal product \n\n\n\nThe statistical considerations\, including the estimation of number of subjects to be enrolled  \n\n\n\nThe regulatory requirements for performing clinical studies with radiopharmaceutical with special focus on diagnostic radiopharmaceuticals and to summarise the particularities of these studies \n\n\n\nThe ethical and medical considerations in common and vulnerable populations \n\n\n\nThe principles of preparing the clinical study protocol  \n\n\n\nThe objectives\, endpoints and outcome measures  \n\n\n\nThe principles of patient selection\, inclusion and non-inclusion criteria \n\n\n\nThe principles of establishment of the standard of truth\, the role of the comparator\, superiority/non-inferiority/equivalence(?) studies) & practical examples\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\n\nPersonnel involved in designing and/or performing phase I/II clinical research with diagnostic radiopharmaceuticals (e.g. nuclear medicine physicians\, pharmacists\, physicists\, nurses\, technologist\, administrative staff). \n\n\n\nPersonnel involved in assessment of the ethical\, medical and methodologic aspects of phase I/II research protocols with diagnostic radiopharmaceuticals. \n\n\n\nAll professionals interested in phase I/II clinical research with diagnostic radiopharmaceuticals \n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nChiara GranaSpeaker \n\n\n\n\n\nBart de KeizerSpeaker \n\n\n\n\n\nCaroline StokkeSpeaker \n\n\n\n\n\nJean-Noel TalbotSpeaker \n\n\n\n\n\n\n\nLuisa Roldao PereiraSpeaker \n\n\n\n\n\nJohn Andrei IagaruSpeaker \n\n\n\n\n\nSona BalogovaSpeaker
URL:https://esmit.eanm.org/event/fundamentals-of-research-part-2/
CATEGORIES:Online Course,Research Methods,Self-paced Online Course,Theranostics
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250425T000000
DTEND;TZID=Europe/Vienna:20260425T235959
DTSTAMP:20260421T101950
CREATED:20250225T141140Z
LAST-MODIFIED:20250605T144111Z
UID:2257-1745539200-1777161599@esmit.eanm.org
SUMMARY:Highlights of Focus Meeting 6: Shaping the Future of Breast Cancer Care with Molecular Imaging
DESCRIPTION:Breast cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death in women worldwide. Despite significant advancements in imaging and treatment\, clinical practice remains heterogeneous across institutions and disciplines. Molecular imaging has a pivotal role in breast cancer care\, from diagnosis to recurrence assessment. To address these discrepancies and define the future direction of imaging in breast cancer\, the European Association of Nuclear Medicine (EANM) devoted its 6th Focus Meeting to this topic\, under the following motto “Shaping the Future of Breast Cancer Care with Molecular Imaging”. \n\n\n\n \n\n\n\nThe aims of this project were: \n\n\n\n\nTo define the role of imaging in breast cancer\, particularly the utility of nuclear medicine techniques in different clinical settings (including initial systemic staging\, assessment of response to therapy\, and detection of recurrence). \n\n\n\nTo reach a multidisciplinary consensus on the current state of the art in nuclear medicine imaging in breast cancer.\n\n\n\nTo generate expert recommendations on how best to guide professionals in their clinical decisions\, beyond the existing guidelines. \n\n\n\nTo identify knowledge gaps and topics with lack of scientific evidence for potential future studies.\n\n\n\n\n \n\n\n\n \n\n\n\nThe recordings in this course are sponsored by Novartis. \n\n\n\n\n\n\n\n\n\nRegister nowEnrol in the online course now for free! Register now\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\n\nIsabel T. RubioSpeaker \n\n\n\n\n\nFrederique Penault LlorcaSpeaker \n\n\n\n\n\nThiemo van NijnattenSpeaker \n\n\n\n\n\nElizabeth DibbleSpeaker \n\n\n\n\n\nTessa BuckleSpeaker \n\n\n\n\n\nKatja Pinker DomenigSpeaker \n\n\n\n\n\n\n\n\n\nSofia Carrilho-VazSpeaker \n\n\n\n\n\nMartina Bašić-KoretićSpeaker \n\n\n\n\n\nDavid GroheuxSpeaker \n\n\n\n\n\nGary UlanerSpeaker \n\n\n\n\n\nGeraldine GebhartSpeaker \n\n\n\n\n\nWolfgang WeberSpeaker \n\n\n\n\n\n\n\n\n\nValeria RomeoSpeaker \n\n\n\n\n\nAlessandra GennariSpeaker \n\n\n\n\n\nKarolien GoffinSpeaker \n\n\n\n\n\nNadia HarbeckSpeaker \n\n\n\n\n\nPascal BaltzerSpeaker \n\n\n\n\n\nMichel van KruchtenSpeaker \n\n\n\n\n\n\n\n\n\nGary Cook Speaker \n\n\n\n\n\nPaola Anna ErbaSpeaker \n\n\n\n\n\nJoana M RibeiroSpeaker \n\n\n\n\n\nCarolien SchröderSpeaker \n\n\n\n\n\nRitse MannSpeaker \n\n\n\n\n\nPhilipp BackhausSpeaker \n\n\n\n\n\n\n\n\n\nMalene Gubbe Hildebrand Speaker \n\n\n\n\n\nFatima CardosoSpeaker \n\n\n\n\n\nAntoinette AttardSpeaker \n\n\n\n\n\nFrancesco SchnettiniSpeaker \n\n\n\n\n\nSofia RiveraSpeaker \n\n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/highlights-of-focus-meeting-6-shaping-the-future-of-breast-cancer-care-with-molecular-imaging/
LOCATION:Online
CATEGORIES:Clinical Nuclear Medicine,Self-paced Online Course
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251030T080000
DTEND;TZID=Europe/Vienna:20271130T170000
DTSTAMP:20260421T101950
CREATED:20240228T100725Z
LAST-MODIFIED:20251118T083202Z
UID:1520-1761811200-1827594000@esmit.eanm.org
SUMMARY:Bringing Alpha Therapies into Clinical Practice
DESCRIPTION:UEMS EACCME has granted the accreditation of 3 CME credits for this event. \n\n\n\n \n\n\n\n \n\n\n\nThis online course offers a comprehensive introduction to alpha therapy in nuclear medicine\, with a focus on the fundamental principles and clinical applications of Alpha-Therapy in the fields of Radiopharmaceutical Sciences\, Oncology and Dosimetry. Alpha Therapy is a cutting-edge cancer treatment using alpha radiation. It represents a form of targeted radionuclide therapy that uses alpha-emitting radioisotopes to deliver lethal doses of radiation directly to cancer cells while sparing healthy tissues. It is highly efficient and lately increasingly explored for scientific purposes in the oncologic domain . With this course we aim at bringing Alpha Therapies into clinical practice through various\, relevant presentations. A panel of experts and EANM members will update you on the type of alpha-emitting radioisotopes available\, describing all important steps required for production and radiopharmaceutical development. The advantages\, but also the challenges related to the use of Alpha therapy will amply be discussed and supported by clinical examples. You will be initiated in the existing and ongoing therapeutic trials\, with the best yet to come. Dosimetry will play a pivotal role in this course\, underlying its role in clinical practice. Finally\, The Alphamet project will be presented\, allowing you to get updated with the latest insights from Theranostics. \n\n\n\n \n\n\n\nRPH \n\n\n\nTargeted Alpha Therapy (TAT) represents a cutting-edge advancement in cancer treatment\, harnessing the potent\, cell-killing power of alpha particles to precisely destroy malignant cells while minimizing damage to surrounding healthy tissue. This part of the course course explores the transformative potential of TAT\, highlighting its exceptional potency\, unique ability to overcome radio-resistance\, and its role in modern theranostics. You’ll gain insight into the selection of optimal alpha-emitting radionuclides\, the biological advantages of short-range high-energy emissions\, and the complex challenges involved in the development\, production\, and clinical translation of these innovative therapies. Join us to deepen your knowledge and be part of the future of targeted radiopharmaceuticals in oncology. \n\n\n\nOncology \n\n\n\n \n\n\n\nIn this part of the course\, participants will explore the main advantages of alpha-emitting radionuclides in oncology\, while also gaining an understanding of the clinical challenges associated with their use. You will become familiar with the key clinical aspects of Alpha-Therapy\, supported by real-world perspectives and case insights. The course also highlights current and upcoming therapeutic trials\, providing valuable knowledge on the future direction of this rapidly evolving field. \n\n\n\nDosimetry \n\n\n\nParticipants will begin by exploring the basic concepts of dosimetry with alpha emitters\, highlighting key differences from beta emitter dosimetry. The course then delves into the clinical relevance of alpha dosimetry\, demonstrating how accurate dose assessments can inform and optimize the management of patients undergoing treatment with alpha radiotherapeutics. In addition\, the course presents the Alphamet project\, a major European initiative that addresses the specific metrological challenges associated with targeted alpha therapies. By examining the goals and contributions of Alphamet\, learners will gain insight into how this research supports the safe and effective integration of alpha therapy into routine clinical practice. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo gain an overview of the main advantages of Alpha-radionuclides\n\n\n\nTo learn about the challenges of alpha emitters\, complex production; transport issues\, waste management and handling\n\n\n\nTo get insights on radiobiology: radiotoxicity & effectiveness\n\n\n\nTo have a comprehensive review of research candidates\n\n\n\nTo provide an overview of the main advantages when using Alpha-Therapy in clinical practice\n\n\n\nTo learn about the clinical challenges when using Alpha-Therapy\n\n\n\nTo get insights into current and future trials focusing on Alpha-Therapy\n\n\n\nTo learn the most basic aspects about dosimetry of alpha emitters showing the main differences with dosimetry of beta emitters\n\n\n\nTo learn how dosimetry results could be used in the management of patients treated with radiopharmaceuticals that include alpha emitters\n\n\n\nTo learn on the Alphamet project\, which addresses the unique and unmet metrological challenges of targeted alpha therapies\, contributing to their safe and optimised implementation into routine clinical practice\n\n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear medicine physicians\, radiologists\, medical oncologists\, urologists\, radiation oncologists\, medical physicists\, biologists\, researchers\n\n\n\nRadiochemists\, radiopharmacists\, physicists\, medical physicists\, biologists\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeClick to see the full event programme. View the Programme\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n\n\nDana NiculaeSpeaker \n\n\n\n\n\nEmma AnaheimSpeaker \n\n\n\n\n\nJanke KleyhansSpeaker \n\n\n\n\n\nMarianna TosatoSpeaker \n\n\n\n\n\nWolfgang FendlerSpeaker \n\n\n\n\n\nMathias ZacherlSpeaker \n\n\n\n\n\n\n\nPablo Mínguez GabiñaSpeaker \n\n\n\n\n\nMike SathekgeSpeaker \n\n\n\n\n\nDaniela Oprea-LagerSpeaker \n\n\n\n\n\nAna Denis-BacelarSpeaker \n\n\n\n\n\nJoe O’SullivanSpeaker \n\n\n\n\n\n\n\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\nEnroll yourselfFind your desired course under ‘Online Courses’  \n\n\n\nEnjoy!Once enrolled\, you get full access to the course contents on the ESMIT eLearning platform \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/bringing-alpha-therapies-into-clinical-practice-2/
LOCATION:Online
CATEGORIES:Clinical Nuclear Medicine,Online Course,Radiopharmaceuticals,Self-paced Online Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251103T000000
DTEND;TZID=Europe/Vienna:20271130T235959
DTSTAMP:20260421T101950
CREATED:20251030T092126Z
LAST-MODIFIED:20260309T102411Z
UID:3146-1762128000-1827619199@esmit.eanm.org
SUMMARY:NucMed Essentials - MSK Basics
DESCRIPTION:UEMS EACCME has granted the accreditation of 5 CME credits for this event. \n\n\n\n \n\n\n\n \n\n\n\nNew ESMIT Learning format: Self-paced online course followed by a live session with the course faculty\, where participants are able to ask their questions live!* \n\n\n\n \n\n\n\n \n\n\n\nNuclear Medicine Essentials: The Basics of MSK provides a comprehensive introduction to musculoskeletal applications in nuclear medicine\, focusing on both diagnostic and therapeutic techniques. Participants will explore the fundamental principles of bone scintigraphy\, including its physiological basis\, imaging protocols\, and wide range of clinical applications\, with emphasis on its continued importance in patient care. The course also delves into advanced imaging through NaF PET\, highlighting its uptake mechanisms\, technical considerations\, and growing role in oncology and other clinical contexts. Building on these diagnostic foundations\, the course transitions into therapeutic strategies\, such as the use of Radium-223 in the treatment of bone metastases\, with attention to efficacy\, safety\, and radioprotection measures. \n\n\n\nBeyond theoretical understanding\, the program emphasizes practical application and clinical relevance. Learners will gain exposure to cutting-edge research\, evidence-based workflows\, and therapeutic innovations in the field. Radiosynovectomy for arthritis treatment is presented as an important example of nuclear medicine’s therapeutic scope\, with procedural insights and expected outcomes supported by real-world case demonstrations. Departmental video presentations supplement each topic\, offering participants a unique opportunity to see workflows and protocols in practice. By the end of the course\, attendees will not only understand the fundamentals of musculoskeletal nuclear medicine but also appreciate its evolving role in modern imaging and therapy.  \n\n\n\n \n\n\n\n \n\n\n\n*The live follow-up session will only be held if there is interest – please submit your questions at the dedicated space on our eLearning platform. The date of the live session will be announced in due time. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\nI. Understand the fundamentals of bone scan techniques: \n\n\n\n \n\n\n\n\nDescribe the theoretical considerations and acquisition protocols for bone scans.\n\n\n\nExplain the clinical applications of bone scans across various pathologies.\n\n\n\n\nII. Gain insights into NaF PET for bone imaging: \n\n\n\n\nSummarize the theoretical considerations and acquisition protocols specific to NaF PET.\n\n\n\nRecognize the essential applications of NaF PET in oncology and other clinical cases.\n\n\n\n\nIII. Explore therapeutic approaches for bone metastases using bone-seeking agents: \n\n\n\n\nReview current theoretical knowledge and recent publications on the treatment of bone metastases.\n\n\n\nIdentify practical considerations and procedural steps involved in bone-seeking agent therapies.\n\n\n\n\nIV. Learn the application of radiosynovectomy in managing arthritis: \n\n\n\n\nDescribe the indications\, procedures\, and expected outcomes of radiosynovectomy for arthritis treatment.\n\n\n\n\n \n\n\n\n \n\n\n\nV. Apply knowledge through visual and practical insights from real-world clinical settings: \n\n\n\n\nAssess clinical workflows and procedural nuances via department video presentations for each session.\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nTechnologists\, nuclear medicine physicians and residents \n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nKnut LiepeSpeaker \n\n\n\n\n\nJules Zhang-YinSpeaker \n\n\n\n\n\nPaolo TurcoSpeaker
URL:https://esmit.eanm.org/event/nucmed-essentials-msk-basics/
CATEGORIES:NucMed Essentials
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251201T100000
DTEND;TZID=Europe/Vienna:20251201T110000
DTSTAMP:20260421T101951
CREATED:20250513T093530Z
LAST-MODIFIED:20251118T083337Z
UID:2534-1764583200-1764586800@esmit.eanm.org
SUMMARY:Japanese vs. European View on Targeted Radionuclide Therapy
DESCRIPTION:This event is a collaboration between ESMIT and JSNM. The aim of the webinar is to compare the approach to targeted radionuclide therapy (TRT) in Japan and in Europe. The webinar will focus on the differences in the TRT environment in Japan vs. Europe\, including regulatory science and radiation protection regulation\, and more. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nNuclear Medicine Physicians \n\n\n\n \n\n\n\nFaculty\n\n\n\n\nTatsuya HigashiSpeaker \n\n\n\nWolfgang FendlerSpeaker \n\n\n\nConrad-Amadeus VoltinModerator \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/japanese-vs-european-view-on-targeted-radionuclide-therapy/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251204T080000
DTEND;TZID=Europe/Vienna:20251205T170000
DTSTAMP:20260421T101951
CREATED:20241017T084515Z
LAST-MODIFIED:20250624T123657Z
UID:1968-1764835200-1764954000@esmit.eanm.org
SUMMARY:Nuclear Medicine in Breast Cancer Based on FOCUS Meeting 6
DESCRIPTION:Breast cancer is the most relevant cancer in women worldwide. It is the second most frequently diagnosed cancer (after lung cancer) and the first leading cause of cancer-related death in women\, being the fourth globally regardless of gender. By 2040\, breast cancer is predicted to increase to over 3 million new cases and 1 million deaths per year. \n\n\n\nStaging patients with breast cancer is challenging due to its heterogeneous nature and presentation. Imaging is of utmost importance in all clinical settings\, particularly\, in staging\, assessing therapy response\, and detecting recurrence. Despite the well-stablished usefulness of radiologic modalities\, Nuclear Medicine has demonstrated an important role to play in breast cancer\, which has been increasingly supported by strong scientific evidence. Considering the patient’s long survival\, the benefits of assessing active tumour in an accurate way\, gain major importance in these patient’s care. \n\n\n\nThe recent equipment and radiopharmaceutical developments have opened the path to improve tumour characterization through several imaging possibilities. Currently\, the challenge is to use the correct combination of equipment and tracer at the right time. Furthermore\, homogenize imaging and clinical procedures is becoming even more important. \n\n\n\nDuring this course\, the highlights from the consensus reached during the multidisciplinary EANM Focus Meeting 6 about Nuclear Medicine diagnostics and therapeutics possibilities will be comprehensively presented and discussed in a close way between the faculty and attendees. \n\n\n\n\n\n\n\nRegister nowRegistration is now open\, save yourself a seat! Register now\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo understand breast cancer as a heterogeneous disease\, its characteristics and evolution;\n\n\n\nTo define the role of nuclear medicine techniques in different clinical settings (initial staging\, assessing therapy response\, and detecting recurrence);\n\n\n\nTo know the potential usefulness of PET tracers beyond FDG in each breast cancer subtype and use of the evolving PET technology & equipment;\n\n\n\nTo discuss future diagnostic and treatment approaches with radiopharmaceuticals.\n\n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nNuclear Medicine physicians\, Radiologists\, Medical Oncologists\, Radiation Oncologists\, Medical students\, Residents\, Nurses\, Nuclear Medicine technologists and Radiographers. \n\n\n\n \n\n\n\n\n\n\n\nProgrammeView the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSofia VazSpeakerLisbon\, Portugal \n\n\n\n\n\nThiemo van NijnattenSpeakerMaastricht\, Netherlands \n\n\n\n\n\nPhilipp BackhausSpeakerMünster\, Germany \n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/nuclear-medicine-in-breast-cancer-based-on-focus-meeting-6/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Clinical Nuclear Medicine,Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251212T133000
DTEND;TZID=Europe/Vienna:20251212T143000
DTSTAMP:20260421T101951
CREATED:20241017T081824Z
LAST-MODIFIED:20251204T110136Z
UID:1944-1765546200-1765549800@esmit.eanm.org
SUMMARY:To AI or not to AI in Neurology: That is the Question
DESCRIPTION:This webinar will explore state-of-the-art AI approaches for advancing neuroimaging\, with a particular focus on quantitative PET. It will cover the entire imaging pipeline\, from preprocessing\, acquisition\, and tomographic reconstruction to quantification\, segmentation\, denoising\, and resolution enhancement\, demonstrating how modern AI can enable more reproducible and robust brain PET biomarkers. Through two expert presentations and practical case examples\, the webinar will showcase how AI-driven methodologies are reshaping neuroimaging research and supporting more accurate diagnosis and disease monitoring. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nLearn the principles behind AI-based quantitative PET methods\n\n\n\nUnderstand how AI can enhance each stage of the neuroimaging pipeline\, from preprocessing and reconstruction to segmentation\, denoising\, and resolution recovery.\n\n\n\nCritically assess when AI meaningfully improves neuroimaging workflows\n\n\n\nRecognize emerging opportunities and challenges in integrating AI tools into brain PET\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nNuclear physicians\, medical physicists\, imaging scientists and radiologists working in PET neuroimaging \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nPablo Aguilar FernándezModerator \n\n\n\n\n\nDimitris VisvikisSpeaker \n\n\n\n\n\nCharalampos TsoumpasSpeaker \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/to-ai-or-not-to-ai-in-neurology-that-is-the-question/
CATEGORIES:AI & Quantification,Live Webinars
END:VEVENT
END:VCALENDAR